Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPAC-5F: European Study Group for Pancreatic Cancer - Trial 5F
2013-003932-56Phase 2Unknown
- Sponsor
- University of Liverpool
- Start
- Mar 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gemcitabine, capecitabine, irinotecan, fluorouracil, folinic acid and 1 more in pancreatic cancer (PC) (4 arms), sponsored by University of Liverpool. Primary endpoint: Recruitment feasibility. Status: unknown.
02
Drugs
gemcitabinecapecitabineirinotecanfluorouracilfolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2013-003932-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003932-56.